Hostname: page-component-74656f9884-rdgjk Total loading time: 0 Render date: 2026-11-07T10:48:54.233Z Has data issue: false hasContentIssue false

Assessing hope at the end of life: Validation of an experience of hope scale in advanced cancer patients

Published online by Cambridge University Press:  12 May 2005

CHERYL L. NEKOLAICHUK
Affiliation:
Alberta Cancer Board, Edmonton, Alberta, Canada
EDUARDO BRUERA
Affiliation:
Department of Palliative Care and Rehabilitation Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas
Rights & Permissions [Opens in a new window]

Abstract

Objective: The purpose of this study was to gather validity evidence for an innovative experience of hope scale, the Hope Differential-Short (HDS), and evaluate its clinical utility for assessing hope in advanced cancer patients.

Methods: A consecutive sampling approach was used to recruit 96 patients from an inpatient tertiary palliative care unit and three hospice settings. Each participant completed an in-person survey interview, consisting of the following measures: HDS (nine items), Herth Hope Index (HHI), hope visual analog scale (Hope-VAS) and Edmonton Symptom Assessment System (ESAS).

Results: Using factor analytic procedures, a two-factor structure for the HDS was identified, consisting of authentic spirit (Factor I) and comfort (Factor II). The HDS factors had good overall internal consistency (α = 0.83), with Factor I (α = 0.83) being higher than Factor II (α = 0.69). The two factors positively correlated with the HHI, Hope-VAS, and one of the ESAS visual analog scales, well-being (range: 0.38 to 0.64) and negatively correlated with depression and anxiety, as measured by the ESAS (range: −0.25 to −0.42).

Significance of results: This is the first validation study of the HDS in advanced cancer patients. Its promising psychometric properties and brief patient-oriented nature provide a solid initial foundation for its future use as a clinical assessment measure in oncology and palliative care. Additional studies are warranted to gather further validity evidence for the HDS before its routine use in clinical practice.

Information

Type
Research Article
Copyright
© 2004 Cambridge University Press
Figure 0

The Hope Differential-Short (HDS) instrument.

Figure 1

Record of participant attrition and outcome upon study completion

Figure 2

Patient characteristics

Figure 3

Summary of Edmonton Symptom Assessment System (ESAS) scores (means and standard deviations).

Figure 4

Obliquely rotated pattern factor loadings for the concept, “hope-abstract,” using the Hope Differential-Short (HDS) (delta = −1, n = 96)

Figure 5

Comparison of the two-factor model for the Hope Differential-Short (HDS) with the three-factor model for the Hope Differential (HD).

Figure 6

Correlations between the two HDS factors and related measures (n = 90)a,b

Figure 7

Correlations between the two factors of the Hope Differential-Short (HDS), the Herth Hope Index (HHI), and the Hope Visual Analog Scale (Hope VAS) (n = 90).